Profissionais de saúde Página 4

JAMA - Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children

JAMA NETWORKMultisystem inflammatory syndrome in children (MIS-C) is the most severe pediatric disease associated with severe acute respiratory syndrome coronavirus 2 infection, potentially life-threatening, but the optimal therapeutic strategy...

CDC - Maximizing Fit for Cloth and Medical Procedure Masks to Improve Performance and Reduce SARS

Centers for Disease Control and PreventionUniversal masking is recommended to slow the spread of COVID-19. Cloth masks and medical procedure masks substantially reduce exposure from infected wearers (source control) and reduce exposure of...

ECDC - Infection prevention and control and preparedness for COVID-19 in healthcare settings

European Centre for Disease Prevention and ControlThis document aims to provide guidance to healthcare facilities and healthcare providers in the European Union/European Economic Area (EU/EEA) and the United Kingdom (UK) on preparedness and...

BMJ - Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

British Medical JournalThe coronavirus disease 2019 (covid-19) pandemic has led to profound worldwide health, economic, and social losses. As of October 2020, more than 40 million people have received a diagnosis of covid-19 and one million...

NEJM - Duration of Culturable SARS-CoV-2 in Hospitalized Patients with Covid-19

The New England Journal of MedicineThe duration of transmissibility of coronavirus disease 2019 (Covid-19) and the associated level of contagion have been uncertain. We cultured severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in...

AMP - Allergic Reactions to COVID-19 Vaccines: An Allergist’s Perspective

Acta Médica PortuguesaThe COVID-19 vaccines approved so far for use in the European Union (EU) include those from Pfizer/BioNTech®, Moderna® and AstraZeneca®. Two severe cases of anaphylaxis that were resolved after treatment were reported on the...

JAMA - Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine

JAMA NETWORKOn December 11, 2020, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine, administered as 2 doses separated by 21...

NEJM - Maintaining Safety with SARS-CoV-2 Vaccines

The New England Journal of MedicineTo date, the development of mRNA vaccines for the prevention of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a success story, with no serious concerns identified in...

WHO - COVID-19 Clinical management: living guidance

World Health OrganizationProviding trustworthy guidance that is comprehensive and holistic for the optimal care of COVID-19 patients, throughout their entire illness is necessary. The previous version of the Clinical management of COVID-19...

AMP - SARS-CoV-2 and Cancer: Beyond Immunosuppression

Acta Médica PortuguesaOver the last year the COVID-19 pandemic has led to more than 83 million cases and 1.8 million deaths worldwide. Several conditions, such as cancer, have been identified as potential risk factors for poor outcomes of...

WHO - Contact tracing in the context of COVID-19

World Health OrganizationContact tracing is a key strategy for interrupting chains of transmission of SARS-CoV-2 and reducing COVID-19-associated mortality. This document provides updated guidance on how to establish contact tracing capacity for...

AMP - The Role of Pharmacovigilance in the COVID-19 Pandemic

Acta Médica PortuguesaA farmacovigilância foi definida pela Organização Mundial da Saúde como a ciência e as atividades relacionadas com a deteção, avaliação, compreensão e prevenção de eventos adversos ou qualquer outro problema de segurança...

WHO - Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding

World Health OrganizationThe conduct of COVID-19 vaccine trials in the context of a candidate vaccine being issued with Emergency Use Designation raises challenging ethical questions, including in relation to the use of placebo controls and...

WHO - mRNA-1273 vaccine (Moderna) against COVID-19 Background document (draft)

World Health OrganizationThe messenger ribonucleic acid (mRNA) vaccine platform has advantages as a pandemic-response strategy, given its efficiency in immunogen design and manufacturing. As mRNA is a non-infectious, non-integrating platform,...

AMP - COVID-19 Vaccine: From Theory to Practice

Acta Médica PortuguesaDesde o primeiro diagnóstico de COVID-19 em Wuhan, até à data atual, foram infetadas pelo vírus SARS-CoV-2, a nível mundial, mais de 64 milhões de pessoas, causando mais de 1,5 milhões de óbitos.1 Desde que foi reconhecida...